序约束多臂多阶段临床试验设计
该研究将治疗效应顺序信息纳入多臂多阶段(MAMS)设计,无需假设参数化剂量-反应或持续时间-反应模型,可高概率识别所有有前景的治疗。设计能强控制家族错误率,并在症状性哮喘研究中展示;模拟显示相比固定样本和传统MAMS设计决策更优,样本量减少约15%。
要点
- 序约束MAMS设计可高概率识别所有有前景的治疗。
- 该设计提供家族错误率的强控制。
- 模拟中相比传统MAMS设计样本量减少约15%。
核心结论
- 将治疗效应顺序信息纳入MAMS框架可在不假设参数化剂量-反应或持续时间-反应模型的情况下高概率识别所有有前景的治疗,并提供家族错误率的强控制。
研究设计与样本
- 研究设计为方法学扩展,将多臂多阶段(MAMS)框架扩展以纳入治疗效应顺序,并在症状性哮喘研究中进行展示,通过模拟比较固定样本设计和传统MAMS设计。
主要发现
- 模拟显示,在考虑的情境中,纳入顺序信息相比传统MAMS设计样本量减少约15%。
- 纳入顺序信息相比固定样本设计和MAMS设计带来更好的决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
One family of designs that can noticeably improve efficiency in later stages of drug development are multi-arm multi-stage (MAMS) designs. They allow several arms to be studied concurrently and gain efficiency by dropping poorly performing treatment arms during the trial as well as by allowing to stop early for benefit. Conventional MAMS designs were developed for the setting, in which treatment arms are independent and hence can be inefficient when an order in the effects of the arms can be assumed (eg, when considering different treatment durations or different doses). In this work, we extend the MAMS framework to incorporate the order of treatment effects when no parametric dose-response or duration-response model is assumed. The design can identify all promising treatments with high probability. We show that the design provides strong control of the family-wise error rate and illustrate the design in a study of symptomatic asthma. Via simulations we show that the inclusion of the ordering information leads to better decision-making compared to a fixed sample and a MAMS design. Specifically, in the considered settings, reductions in sample size of around 15% were achieved in comparison to a conventional MAMS design.
引用
- Serra A, Mozgunov P, Jaki T, et al. An order restricted multi-arm multi-stage clinical trial design. Stat Med. 2022. PMID: 35048391. doi:10.1002/sim.9314
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。